What is RNA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.14B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for RNA?

P/E (TTM) is n/a and 52-week range is $7.63 to $73.06 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s RNA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for RNA?

The company profile lists revenue (TTM) near $41M, net income (TTM) near $-8.63B, EPS (TTM) near $-5.04 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Atrium Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 17.1M shares outstanding, ISIN US04965N1046 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Atrium Therapeutics Inc

$RNA

Health Care · Biotechnology

Run Scenarios

$8.40

+1.69%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Atrium Therapeutics, Inc. operates as a biopharmaceutical company that provides RNA therapeutics services to the heart to transform the standard of care for people living with cardiomyopathies. The company is headquartered in San Diego, California and currently employs 47 full-time employees. The company went IPO on 2026-02-27. Its technology leverages the targeted RNA delivery platform, which combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with oligonucleotides. The company is designed to allow selective targeting of the underlying genetic drivers of disease. Its development pipeline consists of programs that target genetically validated drivers of cardiomyopathy, which include Protein Kinase AMP-Activated Non-Catalytic Subunit Gamma 2 (PRKAG2) and Phospholamban (PLN). Its genetic drivers are associated with PRKAG2 syndrome and PLN cardiomyopathy, which is a genetic heart condition associated with life-threatening forms of heart disease. Its programs are supported by preclinical data, in addition to positive clinical data generated in neuromuscular indications using the same RNA delivery platform technology.

Employees

511

IPO

2026-02-27

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (TTM)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US04965N1046

Headquarters

San Diego, California, US

Shares outstanding

17.1M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

85.18%